HIV/AIDS Co-Infection
Findings from P. Munderi and co-researchers advance knowledge in HIV/AIDS co-infection
Published in AIDS Weekly, May 19th, 2008
"To compare the safety/tolerability of abacavir and nevirapine in HIV-infected adults starting antiretroviral (ARV) therapy in Uganda. Twenty-four-week randomized double-blind trial conducted with 600 symptomatic ARV-naive adults with CD4 < 200 cells/mm(3) allocated to zidovudine/lamivudine plus 300 mg abacavir (A) and nevirapine placebo (n = 300) or 200 mg nevirapine (N) and abacavir placebo (n = 300) twice daily," investigators in London, the United Kingdom report.
"The primary endpoint was any serious adverse event (SAE) definitely/probably or uncertain whether related to blinded nevirapine/abacavir. Secondary endpoints were adverse events leading to permanent...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2008-05-19)
More Articles from AIDS Weekly
- Harvard School of Public Health
Major shift in HIV prevention priorities needed - Lifespan
Prisoner HIV program leads to continuum of medical care after release - Antifungals
Reports outline antifungals study findings from University of Texas - HIV/AIDS
New HIV/AIDS study findings recently were published by R. Sanchezdelarosa and co-researchers - HIV/AIDS
Research conducted at University of Michigan, Medical Department has provided new information about HIV/AIDS - HIV/AIDS
Research on HIV/AIDS reported by scientists at University of North Carolina - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
